Should I buy or sell INmune Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares. View INMB analyst ratings or view top-rated stocks .

What is INmune Bio's stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for INmune Bio's shares. Their INMB share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts price targets for INMB or view top-rated stocks among Wall Street analysts .

How have INMB shares performed in 2024?

INmune Bio's stock was trading at $11.26 at the start of the year. Since then, INMB shares have decreased by 21.8% and is now trading at $8.80. View the best growth stocks for 2024 here .

Are investors shorting INmune Bio?

INmune Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,530,000 shares, an increase of 6.3% from the March 15th total of 1,440,000 shares. Based on an average daily volume of 86,500 shares, the short-interest ratio is currently 17.7 days. Approximately 13.0% of the company's shares are short sold. View INmune Bio's Short Interest .

When is INmune Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our INMB earnings forecast .

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.12. The business earned $0.01 million during the quarter. INmune Bio had a negative net margin of 19,360.00% and a negative trailing twelve-month return on equity of 64.11%. During the same period in the prior year, the firm posted ($0.36) earnings per share.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , Advanced Micro Devices (AMD) , Cidara Therapeutics (CDTX) , Gilead Sciences (GILD) , Cisco Systems (CSCO) , Vaxart (VXRT) , Micron Technology (MU) , Novavax (NVAX) and SCYNEXIS (SCYX) .

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fermata Advisors LLC (0.17%). Insiders that own company stock include David J Moss , Mark William Lowdell , Raymond Joseph Tesi , Scott Juda and Timothy J Schroeder . View institutional ownership trends .

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free INMB Stock Alerts

$8.80

+0.37 (+4.39%)

(As of 04/18/2024 ET)

Compare

Today's Range: $8.40
▼
$8.89
50-Day Range: $8.43
▼
$14.01
52-Week Range: $6.50
▼
$14.74

Volume: 97,911 shs
Average Volume: 104,723 shs
Market Capitalization: $160.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Get INmune Bio alerts:

INmune Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 81.8% Upside
$16.00 Price Target
Short Interest: Bearish
13.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.46
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

766th out of 918 stocks

Biological Products, Except Diagnostic Industry

134th out of 154 stocks

3.5

Analyst's Opinion

Consensus Rating
INmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
INmune Bio has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
13.03% of the float of INmune Bio has been sold short.
Short Interest Ratio / Days to Cover
INmune Bio has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.
Change versus previous month
Short interest in INmune Bio has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
INmune Bio does not currently pay a dividend.
Dividend Growth
INmune Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INMB.

1.9

News and Social Media Coverage

News Sentiment
INmune Bio has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for INmune Bio this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, INmune Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 12.72% of the stock of INmune Bio is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of INmune Bio is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of INmune Bio is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
INmune Bio has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About INmune Bio Stock (NASDAQ:INMB)

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INMB Stock News Headlines

April 16, 2024 | americanbankingnews.com

INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest

April 8, 2024 | finance.yahoo.com

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 8, 2024 | globenewswire.com

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

April 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)

April 1, 2024 | finance.yahoo.com

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

March 31, 2024 | finance.yahoo.com

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 30, 2024 | seekingalpha.com

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 29, 2024 | finance.yahoo.com

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

March 29, 2024 | finanznachrichten.de

INmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

March 28, 2024 | globenewswire.com

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

March 26, 2024 | globenewswire.com

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

March 13, 2024 | globenewswire.com

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

March 6, 2024 | finanznachrichten.de

INmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments

March 5, 2024 | globenewswire.com

INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™

February 17, 2024 | finance.yahoo.com

INMB Jun 2024 25.000 call

February 16, 2024 | finance.yahoo.com

INMB Mar 2024 20.000 call

February 16, 2024 | finance.yahoo.com

INMB Mar 2024 12.500 put

February 15, 2024 | finance.yahoo.com

INMB Feb 2024 15.000 put

February 12, 2024 | finance.yahoo.com

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7, 2024 | finance.yahoo.com

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

February 4, 2024 | finance.yahoo.com

Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company

February 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach

February 1, 2024 | msn.com

Inmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 Enrollment

January 31, 2024 | msn.com

FDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trial

See More Headlines

Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:INMB
CUSIP: N/A
CIK: 1711754
Web: www.inmunebio.com
Phone: (858) 964-3720
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.00
High Stock Price Target: $16.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +81.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,010,000.00
Net Margins: -19,360.00%
Pretax Margin: -19,360.00%
Return on Equity: -64.11%
Return on Assets: -45.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.16
Quick Ratio: 2.16

Sales & Book Value

Annual Sales: $160,000.00
Price / Sales: 1,001.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.07 per share
Price / Book: 4.25

Miscellaneous

Outstanding Shares: 18,200,000
Free Float: 11,519,000
Market Cap: $160.16 million
Optionable: Optionable
Beta: 1.99

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Raymond Joseph Tesi M.D. (Age 68)
Co-Founder, President, CEO, Chief Medical Officer & Chairman
Comp: $591.5k
Mr. David J. Moss M.B.A. (Age 54)
CFO, Treasurer & Secretary
Comp: $445.16k
Dr. Mark William Lowdell BSc (Age 61)
FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer
Comp: $152.01k
Mr. Joshua S. Schoonover Esq.
General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INMB Stock Analysis - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares.
View INMB analyst ratings or view top-rated stocks.
What is INmune Bio's stock price target for 2024?: 1 Wall Street analysts have issued 12 month target prices for INmune Bio's shares. Their INMB share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price.
View analysts price targets for INMB or view top-rated stocks among Wall Street analysts.
How have INMB shares performed in 2024?: INmune Bio's stock was trading at $11.26 at the start of the year. Since then, INMB shares have decreased by 21.8% and is now trading at $8.80.
View the best growth stocks for 2024 here.
Are investors shorting INmune Bio?: INmune Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,530,000 shares, an increase of 6.3% from the March 15th total of 1,440,000 shares. Based on an average daily volume of 86,500 shares, the short-interest ratio is currently 17.7 days. Approximately 13.0% of the company's shares are short sold.
View INmune Bio's Short Interest.
When is INmune Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our INMB earnings forecast.

How were INmune Bio's earnings last quarter?: INmune Bio, Inc. (NASDAQ:INMB) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.12. The business earned $0.01 million during the quarter. INmune Bio had a negative net margin of 19,360.00% and a negative trailing twelve-month return on equity of 64.11%. During the same period in the prior year, the firm posted ($0.36) earnings per share.
What other stocks do shareholders of INmune Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).
Who are INmune Bio's major shareholders?: INmune Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fermata Advisors LLC (0.17%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder.
View institutional ownership trends.
How do I buy shares of INmune Bio?: Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INMB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial